Recent Safety Data: Implications for Use of Proton Pump Inhibitors

DECEMBER 21, 2016
Supported by an unrestricted grant from P&G.



Heartburn is a common symptom; in North America, heartburn is experienced at least once per week by an estimated 18% to 28% of adults.1 A variety of OTC treatment options are available for heartburn management, including proton pump inhibitors (PPIs), which have a well-studied safety profile that has been verified in multiple randomized controlled trials, as well as decades of clinical experience.2-4 Very small theoretical risks with PPIs have been identified in observational studies of patients receiving therapy over months to years5-11; these studies do not apply to short-term treatment, as is recommended with OTC use.
 
Pharmacy Times® has made available a review of practical information regarding recent safety data on PPIs, to assist pharmacists in educating their patients and providing guidance regarding appropriate product use.
 
References
  1. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871-880. doi: 10.1136/gutjnl-2012-304269.
  2. Chapman DB, Rees CJ, Lippert D, Sataloff RT, Wright SC Jr. Adverse effects of long-term proton pump inhibitor use: a review for the otolaryngologist. J Voice. 2011;25(2):236-240. doi: 10.1016/j.jvoice.2009.10.015.
  3. Davies M, Wilton LV, Shakir SA. Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England. Drug Saf. 2008;31(4):313-323.
  4. Klinkenberg-Knol EC, Nelis F, Dent J, et al; Long-Term Study Group. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118(4):661-669.
  5. Arora P, Gupta A, Golzy M, Patel N, et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol. 2016;17(1):112. doi: 10.1186/s12882-016-0325-4.
  6. Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265(5):419-428. doi: 10.1007/s00406-014-0554-0.
  7. Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410-416. doi: 10.1001/jamaneurol.2015.4791.
  8. Atri A, Gerson LB. Continued questions about whether avoidance of proton pump inhibitors can reduce risk of dementia. Gastroenterology. 2016;151(3):555-558. doi: 10.1053/j.gastro.2016.07.028.
  9. Wijarnpreecha K, Thongprayoon C, Panjawatanan P, Ungprasert P. Proton pump inhibitors and risk of dementia. Ann Transl Med. 2016;4(12):240. doi: 10.21037/atm.2016.06.14.
  10. Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153-3163.
  11. Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238-246. doi: 10.1001/jamainternmed.2015.7193.


 

The Oncology Care Pharmacist in Health-System Pharmacy 
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.


 

Pharmacy Times Strategic Alliance
 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.